Haematuria and When to Worry

Ms Anna Walsh, Consultant Urologist January 25th 2025



Internal use only by approved personnel. Unpublished Work © Beacon Hospital. All rights Reserved. In Strict Confidence.

THIS IS MODERN MEDICINE

Who am I?









Case 1

52 YO





NVH definition

BAUS/NICE:

2 out of 3 occasions, NO urininfection

2+ or 3+ on dipstick urinalysis PPV , does not need confirmi microscopy

Trace or 1+, confirm on micro and 10 RBC/ microlitre is rego significant



ne dipstick should prompt c evaluation.

blood cells per high-(RBC/HPF) on a properly ample.




Dipstick sensitivity >90%

- Poor specificity however
- 1+ on dipstick = 10-40 RBC/hpf



Microscopy

- >3 RBC/hpf
- False negative with Delayed samples and cell lysis





Haematuria clinic referral guidelines UK 2015

Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) for bladder cancer if they are:

- aged 45 and over and have:
 - unexplained visible haematuria without urinary tract infection or
 - visible haematuria that persists or recurs after successful treatment of urinary tract infection, or
- aged 60 and over and have unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test. [new 2015]


Consider non-urgent referral for bladder cancer in people aged 60 and over with recurrent or persistent unexplained urinary tract infection. [new 2015]



Low-risk (meets all criteria)	Intermediate-risk (meets any one criteria)	High-risk (meets any one criteria)
 Age <50 for women and <40 for men 	 Age 50-59 for women and 40-59 for men 	 Age >60 years old
 Never smoker, or smoking history <10 pack years 	 Smoking history 10-30 pack years 	 Smoking history >30 pack years
years	 11-25 RBC/HPF on urinalysis 	 >25 RBC/HPF on urinalysis
 3-10 RBC/HPF on urinalysis 	 Additional risk-factors for urothelial cancer 	 History of visible haematuria
 No additional risk-factors for urothelial cancer 	 Low-risk patient with persistent microscopic haematuria on repeat urinalysis 	



Investigation:



Haematuria clinic referral guidelines UK

Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) for bladder cancer if they are:

- aged 45 and over and have:
 - unexplained visible haematuria without urinary tract infection or
 - o visible haematuria that persists or recurs after successful treatment of urinary tract infection, or
- aged 60 and over and have unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test. [new 2015]


Consider non-urgent referral for bladder cancer in people aged 60 and over with recurrent or persistent unexplained urinary tract infection. [new 2015]



Low-risk (meets all criteria)	Intermediate-risk (meets any one criteria)	High-risk (meets any one criteria)
 Age <50 for women and <40 for men 	 Age 50-59 for women and 40-59 for men 	 Age >60 years old
 Never smoker, or smoking history <10 pack years 3-10 RBC/HPF on urinalysis No additional risk-factors for urothelial cancer 	 Smoking history 10-30 pack years 11-25 RBC/HPF on urinalysis Additional risk-factors for urothelial cancer Low-risk patient with persistent microscopic haematuria on repeat urinalysis 	 Smoking history >30 pack years >25 RBC/HPF on urinalysis History of visible haematuria




NVH and negative flexible cystoscopy/Ultrasound





Persistent VH and negative flexible cystoscopy/CT



Consider renal arteriography, retrograde ureteropyelogram, cystoscopy/bx



VH and UTI case

45 YO










Recurrent UTI



Expert Rev Vaccines. 2012; 11(6): 663–676.



USS is beneficial in women with persistent and relapsing infections to exclude or identify complications

Franco Best Pract Res Clin Obstet Gynaecol 2005

118 patients – 8% significant abnormalities on flexi cysto – NPV of imaging 99% = "no cystoscopy in women without risk factors and normal imaging" Lawrentschuk Int J Urol 2006

Proteus UTI and urolithiasis:

- 44% of bacteraemic Proteus UTI have urolithiasis
- 24% of non-bacteraemic Proteus UTI have urolithiasis Chen et al 2012



Management



Cranberry

D-mannose Methanamine Hippurate Topical Vaginal Oestrogen

Oral vaccine



Prophylactic Self start



Cystistat IAluRil Gentamicin



In, then out, then in again...

Can Cranberries Contribute to Reduce the Incidence of Urinary Tract Infections? A Systematic Review with Meta-Analysis and Trial Sequential Analysis of Clinical Trials. Luís, Ângelo et al, The Journal of Urology 2017, Volume 198, Issue 3, 614 - 621

CRANBERRY PRODUCTS REDUCE URINARY TRACT INFECTIONS

 B trials
 32.59%

 RR 0.675 (95% CI: 055-0.79)

 Significant risk reduction

 Most helpful in pts with recurrent UTIs

 LINE DURNAL

 EXECUTION OF CITAL DURY

Systematic review, meta-analysis and trial sequential analysis

Copyright © 2017 American Urological Association Education and Research, Inc., Published by Elsevier



In a randomised placebo-controlled non-blinded clinical trial, it was shown that a daily dose of 2 g D-mannose was significantly superior to placebo and as effective as 50 mg nitrofurantoin in preventing UTIs.

 D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. Kranjčec et al World Journal of Urology 2014, Volume 32(1),pp 79–84

MINI REVIEW - INFECTIONS | ARTICLES IN PRESS

Role of D-Mannose in the Prevention of Recurrent Urinary Tract Infections: Evidence from a Systematic Review of the Literature

Rena Kyriakides • Patrick Jones • Bhaskar K. Somani 😤 🖂

Published: September 21, 2020 * DOI: https://doi.org/10.1016/j.euf.2020.09.004



Vaginal Oestrogen

Vaginal oestrogen cream (estriol cream 0.5mg applied topically at night for 2weeks then twice weekly) for 8months significantly reduced the risk of recurrent infection in postmenopausal women compared with placebo (16.0% versus 62.8%, NNT 3 [range 2 to 4]; high quality evidence).

 Raz R and Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993; 329: 753–756.







Methanamine Hippurate

Compared to antibiotic prophylaxis, methenamine is

- Non inferior
- Less costly
- Considered as alternative to daily abx prophylaxis in women/female genitourinary system

Study protocol | Open Access | Published: 09 November 2018

ALternatives To prophylactic Antibiotics for the treatment of Recurrent urinary tract infection in women (ALTAR): study protocol for a multicentre, pragmatic, patient-randomised, non-inferiority trial

Rebecca Forbes, Ased Ali, Alaa Abouhajar, Catherine Brennand, Heather Brown, Sonya Carnell, Thomas Chadwick, Ian Eardley, Jan Lecouturier, Helen Mossop, Ian Pearce, Robert Pickard, Nikesh Thiruchelvam, Katherine Walton, Jennifer Wilkinson & Chris Harding 🖂

Trials19, Article number: 616 (2018)Cite this article15kAccesses6Citations8AltmetricMetrics



Vaccines – Uromune (MV140)/Uro-vaxom/Urovac

(NEJM

Clinical Trial > Eur Urol. 1994;26(2):137-40. doi: 10.1159/000475363.

Uro-Vaxom and the management of recurrent urinary tract infection in adults: a randomized multicenter double-blind trial

P Magasi 1, J Pánovics, A Illés, M Nagy

Affiliations + expand PMID: 7957468 DOI: 10.1159/000475363

Abstract

__. ..

A total of 112 patients with recurrent lower urinary tract infection (UTI) completed the 6-month period of the trial. Patients were treated for 3 months, under double-blind conditions, with one capsule daily of either Uro-Vaxom (UV) or placebo, together with an antibiotic or chemotherapeutic agent when necessary, and observed for a further 3 months. During the 6 months of the trial a significant decrease in the number of recurrences (p < 0.0005) was noted in the UV group as compared to the placebo group. A total of 67.2% of the patients had no recurrences (p < 0.0005). The incidence of bacteriuria (germs > or = 10(5)/ml), dysuria and leukocyturia was significantly reduced. UV was well tolerated, no side effects were recorded during the trial. The drug is a useful adjuvant for the management of UTIs and for the prevention of recurrences.



Long term prophylaxis can range from 4 mths to 5 yrs

 95% will remain UTI free but 50% relapse following cessation Nicolle et al. Am J Med 2002

Cochrane review of RCT's - RR 0.21 for single recurrence (NNT 1.85) but RR after completion of prophylaxis 0.82

Albert et al. Cochrane Database 2004

Single randomised study found prophylactic nitrofurantoin superior to oestrogen Raz et al. Clin Infect Dis 2003



85-95% of women with previous UTI can self diagnose successfully Gupta et al. Ann Intern Med 2001

Clinical and Microbiological cure rates > 90% Best used in motivated women with previous culture confirmed cystitis Hooton NEJM 2012

Advantages are less antimicrobial exposure and high patient satisfaction rates

Post coital antibiotics reserved for group where it has been identified as the dominant risk factor.



Intravesicle treatments

GAG replacement therapy

CEOG Clinical and Experimental Obstetrics & Gynecology

Long-term efficacy of intravesical instillation of hyaluronic acid/chondroitin sulfate in recurrent bacterial cystitis: 36 months' follow-up

D. De Vita1*, M. Madonia2*, E. Coppola¹, C. Sciorio³, S. Giordano⁵, S. Dessole⁴, G. Capobianco⁴

¹Chronic Pelvic Pain Centre, Dep. of Obstetrics and Gynaecology. Ospedale S. Maria Della Speranza, Battipaglia ¹Institute of Urology, University of Sassari, Sassari, 'Ostetricia e Ginecologia, ASL Napoli 2 Nord, Naples ⁴Gynecologic and Obstetric Clinic, Dep. of Surgical, Microsurgical and Medical Sciences, University of Sassari (Italy) ³Division of Plastic Surgery, Department of Surgery, Turku University Hospital, OS Turku (Finland)

Summary

Purpose of Investigation: To compare the efficacy and safety of intravesical instillation of hyaluronic acid/chondroitin sulfate with conventional long-term antibiotic prophylaxis in women with recurrent bacterial cystitis. *Materials and Methods*: In this analysis of a prospective study, where women with recurrent bacterial cystitis were randomised to intravesical hyaluronic acid 800 mg/chondroitin sulfate 1,000 mg (group 1) or long-term antibiotic prophylaxis (group 2 – control group), patients in group 1 were evaluated 36 months after treatment. Outcomes included cystitis recurrence, subjective pain symptoms based on a visual analogue scale (VAS), three-day voiding, pelvice pain and urgency/frequency symptomes (PUF scale), sexual function questionnaire, quality of life based on King's Health Questionnaire (KHQ), maximum cystometric capacity (MCC), and adverse events. *Results*: Twelve women (mean ± standard deviation 59.3 ± 13.9 years old) underwent follow-up at 36 months after treatment. There were improvements in all efficacy evaluations at 36 months' follow-up, with significantly favourable mean changes from baseline in cystitis frequency (-5.4 episodes/year; p < 0.001), three-day voiding (-10.7 voids; p = 0.002), urinary VAS (-6.7 points; p < 0.001), PUF (-14.2 points; p < 0.001), and KHQ (-34.0; p < 0.001) scores, and MCC (+131.7; p < 0.001). No adverse events were reported. *Conclusions*: Intravesical hyaluronic acid/chondroitin sulfate significantly reduced cystitis recurrence and associated symptoms and was well tolerated in wome with recurrent bacterial cystitis at 36 months' after treatment.

Key words: Chondroitin sulfate; Hyaluronic acid; Intravesical instillation; Recurrent bacterial cystitis; Recurrent urinary tract infection

Antibiotics

Review > Int Urogynecol J. 2022 May;33(5):1125-1143. doi: 10.1007/s00192-021-05042-z. Epub 2022 Jan 4.

Efficacy of antimicrobial intravesical treatment for uncomplicated recurrent urinary tract infections: a systematic review

Meghana Reddy ¹, Philippe E Zimmern ²

Affiliations + expand PMID: 34982189 DOI: 10.1007/s00192-021-05042-z

Abstract

Introduction and hypothesis: Intravesical antimicrobials (IVA) provide a localized modality of treatment for recurrent urinary tract infections (rUTIs). Owing to the sporadic use of these treatments, we conducted a systematic review on the efficacy of IVA in the management of uncomplicated rUTIs.

Methods: A systematic review was conducted for all English language articles from inception to April 2021 utilizing the Cochrane and Preferred Reporting Items for Systematic Reviews and Meta-Analyses standards with the following databases: PubMed, OVID Embase, Biomed Central, and Scopus. References were cross-examined for further articles. Risk of bias was assessed in the articles included using the Cochrane and Joanna Briggs Institute tools.

Results: The initial search resulting in 476 titles led to 15 full-text articles. Of the 13 in the final review (2 RCTs), 3 used gentamicin and 10 used hyaluronic acid IVA. These included 764



Haematuria clinic referral guidelines UK

Refer people using a suspected cancer pathway referral (for an appointment within 2 weeks) for bladder cancer if they are:

- aged 45 and over and have:
 - unexplained visible haematuria without urinary tract infection or

visible haematuria that persists or recurs after successful treatment of urinary tract infection, or

 aged 60 and over and have unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test. [new 2015]

Consider non-urgent referral for bladder cancer in people aged 60 and over with recurrent or persistent unexplained urinary tract infection. [new 2015]



Low-risk (meets all criteria)	Intermediate-risk (meets any one criteria)	High-risk (meets any one criteria)
 Age <50 for women and <40 for men 	 Age 50-59 for women and 40-59 for men 	► Age >60 years old
 Never smoker, or smoking history <10 pack 	 Smoking history 10-30 pack years 	 Smoking history >30 pack years
years	 11-25 RBC/HPF on urinalysis 	► >25 RBC/HPF on urinalysis
 3-10 RBC/HPF on urinalysis 	 Additional risk-factors for urothelial cancer 	 History of visible haematuria
 No additional risk-factors for urothelial cancer 	 Low-risk patient with persistent microscopic 	
	haematuria on repeat urinalysis	




VH case - UC

87 yo male









Cancer and haematuria, the studies

2018 Wh Prc Wei S on be Affilin

PLATI





Risk Factors for Urothelial cancer

Smoking

Strong family history of bladder cancer (2 or more relatives)

Occupational exposure to carcinogens

Pelvic irradiation


Cyclophosphamide treatment

Previous schistosomiasis infection

Significant filling bladder symptoms in the absence of a urinary infection (urgency, frequency, dysuria)




Renal cancer





Hereditary malignancy



Families with 2 or more affected with RCC Multifocal/bilateral tumours Non-renal manifestations Early age of onset (<46 years) Clinical/histopathological diagnosis

Germline mutation analysis Multi-disciplinary approach Appropriate surgical intervention (early with HLRCC)



Haematuria clinic

Female, menopausal LUTS, recurrent UTI Urological malignancy

- Renal cancer
- Upper tract urothelial cancer
- Bladder cancer
- Prostate cancer

Hereditary/genetic malignacy



Thank you

